| 伍楚蓉,张启周,杨 文.尼妥珠单抗同期调强放疗及化疗治疗食管癌的临床研究[J].肿瘤学杂志,2014,20(6):500-503. |
| 尼妥珠单抗同期调强放疗及化疗治疗食管癌的临床研究 |
| Clinical Study on Nimotuzumab Combined with Intensity-modulated Radiotherapy and Chemotherapy for Esophageal Cancer |
| 投稿时间：2013-07-31 |
| DOI：10.11735/j.issn.1671-170X.2014.06.B014 |
|
 |
| 中文关键词: 食管肿瘤 尼妥珠单抗 药物疗法 放射疗法 |
| 英文关键词:esophageal neoplasms nimotuzumab drug therapy radiotherapy |
| 基金项目: |
|
| 摘要点击次数: 2149 |
| 全文下载次数: 1088 |
| 中文摘要: |
| 摘 要：［目的］ 探讨尼妥珠单抗同期调强放疗及化疗治疗食管癌的疗效及不良反应。［方法］ 经病理确诊的食管癌初诊患者32 例分为两组，对照组(n=16)采用调强放疗及化疗；观察组(n=16) 除调强放疗及化疗外，每周放疗前进行尼妥珠单抗100mg治疗，共6～7 次。［结果］ 放疗结束后2个月复查完全缓解(CR)率，观察组为87.5%，对照组为68.8%，两组有效(RR)率均为100.0%；随访2 年对照组和观察组的局部区域控制率为87.5%和100%(P＞0.05)，而无远处转移生存率分别为62.5%和81.3%(P＞0.05)。两组主要不良反应为放射性食管黏膜炎、放射性皮炎和恶心呕吐、粒细胞减少、疲乏等，无皮疹及过敏反应发生，患者均能耐受，观察组发生2 级以上放射性食管黏膜炎、粒细胞减少较对照组偏高，但差异无统计学意义(P＞0.05)。［结论］ 尼妥珠单抗可提高食管癌对放疗的敏感性，提高有效率及降低复发转移率，安全有效。 |
| 英文摘要: |
| Abstract：［Purpose］ To study the efficacy and side effects of nimotuzumab combined with concurrent intensity-modulated radiotherapy and chemotherapy in the treatment for esophageal cancer. ［Methods］ Thirty-two esophageal cancer patients pathologically proved were divided into two group，control group(n=16) who received 3D conformal therapy and period chemotherapy，and observation group(n=16) received 100mg nimotuzumab administration before intensity modulated radiation therapy and period chemotherapy. All patients received 6 to 7 cycles. ［Results］ Two months after radiotherapy，the complete remission rate in observation group was 87.5% while in control group it was 68.8%. The response rates were both 100.0%. The local regional control rates after 2 years’ follow-up were 87.5% in control group and 100% in observation group(P>0.05)，while the non-metastasis survival rates were 62.5% and 81.3% respectively(P>0.05). The toxicity in the 2 groups included radiation esophageal mucosal inflammation，radiation dermatities and nausea and vomiting，granulocytopenia，fatigue，but neither erythra nor allergy was found. Despite the rates of grade-2 radiation esophageal mucosal inflammation and granulocytopenia in observation group was higher than that in control group but without significant difference(P>0.05)． ［Conclusion］ Nimotuzumab could enhance the esophageal cancer patients’sensitivity on radiotherapy，increase response rate，and decrease recurrent rate．Ｉt is a safe and effective agent for esophageal cancer. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |